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1.1 Genomic biomarkers for cancer diagnostics and
prognostics
The increasing availability of DNA microarray technology has spawn a large num-
ber of genome-scale gene expression profiling studies in cancer. These cancer microar-
ray studies have shown potential of identifying genomic biomarkers that outperform
standard clinical parameters as diagnosis and prognosis targets. For instance, in
prostate cancer, screening for elevated serum prostate-specific antigen (PSA) level
has become a standard clinical test for early detection, but is known to result in high
percentage of false positives. Only about 30% of men with a “positive” PSA have a
positive biopsy. New biomarkers are needed to improve early detection of prostate
cancer. In this respect, studies have explored the utility of microarrays in identifying
gene expression “signatures” with activated or repressed expression profiles in the
disease status as potential diagnostic targets (Dhanasekaran et al., 2001, Luo et al.,
2001, Welsh et al., 2001). Another example pertains to genomic studies in breast
cancer. Estrogen Receptor (ER) positive status is a well-known predictor of patient
response to hormonal therapy. In contrast, ER negative breast carcinomas generally
lack effective treatment options and are correlated with higher risk of developing
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disease recurrences. Much effort has been dedicated to finding gene expression sig-
natures that can provide treatment guidance and predict patient recurrence outcome
above and beyond standard clinical parameters such as ER status, lymph node sta-
tus, stage of the disease (Huang et al., 2003, Sorlie et al., 2001, Sotiriou et al., 2003,
van’t Veer et al., 2002, Wang et al., 2005). For a review, see Van de Vijver (2005).
Overall, genome-scale expression profiling has been a prolific approach in identifying
novel molecular targets that delineate cancer subtypes and survival outcome.
1.2 Integrative analysis of DNA microarrays
A caveat in cancer genomic studies is that predictive genes identified in one study
often can not be validated in another. When findings from independent studies are
cross-examined, the individual gene signature sets tend to have little overlap in terms
of gene identities. Such lack of concordance may be attributed to the differences in the
study cohorts and analysis strategies. But a prominent source of variation comes from
the use of different array platforms. Some of the commonly used microarray platforms
include two-color spotted cDNA arrays, Affymetrix GeneChip arrays, and two-color
long oligonucleotide arrays. Differences among these technologies include one- or
two-channel formats, cDNA or oligonucleotide, in-house spotted or commercially
developed. Expression profiling data generated from distinct array platforms can
vary significantly in measurement scale and variance structure. In addition, the
large p small n nature of microarray data also contributes to the problem. A search
in a space of thousands of genes with a handful of samples does not lead to the gene
selection stability one desires (Ein-Dor et al., 2005, 2006).
Integrative analysis of multiple studies, however, has shown great promise in com-
piling common gene expression patterns across data sets and even over distinct cancer
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types (Rhodes et al., 2004). Various methods have been proposed for combining re-
sults across studies. Among these, Rhodes et al. (2002) proposed methods to summa-
rize across studies the P-values from a two-sample test of gene expression differences
between cancer and normal tissues. Choi et al. (2003) suggested combining effect
size using a hierarchical model, where the estimated effect size in individual studies
follows a normal distribution with mean zero and between study variance τ 2. From
a Bayesian perspective, Wang et al. (2004) used data from one study to generate a
prior distribution and subsequent microarray studies to update the parameter values
of the prior.
A recent application of Bayesian mixture modeling to Microarray classification
problems by Parmigiani et al. (2002) has given new insights into integrating different
studies. The basic idea is to estimate the probability of over-, under- or normal ex-
pression for gene sample combinations given the observed expression measurements.
As a result, poe (i.e., probability of expression) was introduced as a new scale and
used in the context of molecular classification. The platform-free property of this
scale, however, has motivated its potential use as a data transformation technique
to facilitate data integration. In Chapter II, I propose an approach to meta-analyses
of microarrays that is based on poe.
1.3 Analyzing protein expression data from Tis-
sue Microarrays
DNA microarray studies often yield a few hundred candidate cancer genes display-
ing differential expression that is associated with a phenotype. Only a small portion
of which will be eventually validated for the corresponding expression changes at
the protein level. Translating these discovery-type findings into clinical relevance is
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an important task. The advent of Tissue Microarray (TMA) technology (Kononen
et al., 1998) has provided a proteomic platform for validation studies of those target
discoveries. It has quickly become an integral part of cancer biomarker development
(Figure 1.1). The main statistical issue in TMA data anlaysis is repeated measure-
ments in each tumor. Immunohistochemical (IHC) staining assays are performed on
multiple biopsy tissue elements of 0.6 mm in diameter and 4-8 µm in thickness to
assess protein expression. The resulting staining pattern is traditionally evaluated
by a pathologist and given an integer score on the scale of 0-3 to indicate no, weak,
moderate, and strong staining. A primary goal of interest is to summarize such score
across the multiple tissue samples and then associate with clinical outcomes of that
tumor.
In Liu et al. (2004), the authors are concerned with various pooling methods
(such as using the mean, median, minimum and maximum of the repeated mea-
surements), and subsequent dichotomization of the scores. They propose to use
a deviance-based survival tree (LeBlanc and Crowley, 1992) and a bump hunting
(Friedman and Fisher, 1999) method for choosing the best predictor score for pa-
tient survival outcome analysis. However, TMA core-level repeated expression data
harbor substantial biological and experimental variability. Those summary scores
can yield large variability without explicitly adjusting for the intra-tumor expression
variation.
To deal with repeated measurements, I propose a measurement error approach for
analyzing quantitative protein expression data from TMA experiments. Our main
interest is parameter estimation in proportional hazards models to associate the
repeated core-level expression measures with patient survival outcome. In a two-stage
method, I introduce a Latent Expression Index (LEI) to adjust for 1) the intra-tumor
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variation, 2) the number of repeated measures, and 2) clinical covariates. A joint
model is further established for simultaneous inference on the expression data and
survival. When the quantitative intensity measure from the Chromavision system
(Chromavision, San Juan Capistrano, CA) is concerned, a normality assumption is
used on the logarithm transformed intensity measure.
The work in the final Chapter of this dissertation involves a generalization of the
error model in Chapter III. One extension is to incorporate both the proportion and
intensity measure of staining to summarize the protein expression profile of a tumor.
For data based on a pathologist’s evaluation, several empirical methods have been
used. For example, a product score takes the product of the staining intensity level
(0,1,2,3) and a crude proportion measure (0-100%). Another scoring system divides
the staining proportion into six categories and then adds up with the intensity level
(Allred et al., 1998).
Etzioni et al. (2005) pointed out that constructing such summary scores led to
loss of information. The authors considered a compositional data analysis. For each
tumor i, the authors define the observation vector as (Xi1, Xi2, ...XiK); i = 1, · · · , n.
Here Xij denotes the proportion of staining at intensity level j = 1, · · · , K, and
subjects to the constraint that
∑K
j=1 Xij = 1. An additive log-ratio transformation
is taken on Xij and the transformed vector is then modeled as a multivariate normal
distribution. In addition, a cumulative logit model is proposed to incorporate the
order of the intensity levels. A major limitation of this method is that the stain-
ing proportion and intensity levels are considered error-free measures while in fact
they represent a coarse evaluation at best from a pathologist’s manual reading. In
addition, this method is designed for traditional immunohistochemical experiments,
which differ from quantitative TMA expeiments in two aspects: subjective (cate-
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gorical) versus automated (continuous) data; one large section of the tumor versus
multiple small sections. The proposed methods by Etzioni et al. (2005) is not directly
applicable to quantitative TMA data.
In Chapter IV, I introduce a Cell Mixture Model (CMM) to incorporate both
staining proportion and intensity measures from quantitative TMA data adjusting
for measurement variability. Specifically, the protein expression profile measured
from an individual core is modeled as a mixture distribution of a point-mass at zero
to account for the proportion of non-staining and a continuous distribution for the
intensity measure of positive staining. The whole-tumor expression profile is then
reconstructed by aggregating over the individual mixture distributions. Here we deal
with Chromavision data with quantitative measures that are considered substantially
more accurate than those from a pathologist’s scoring. However, measurement error
still exists due to various reasons. A major source is the scarcity of the measure-
ments taken per tumor. In TMA studies, the challenge is to estimate the whole-tumor
expression characteristics with an average of three tissue cores each of 0.6 mm in di-
ameters from a tumor that can be 100 times larger. An analogy is to estimate the
characteristics of the population in the United States with data collected in three rep-
resentative cities. In survey sampling problems, small area estimation often involves
parameter estimation for small sub-population of interest. Hierarchical Bayes (HB)
and Empirical Bayes (EB) approaches have been effective with continuous data. For
a thorough review of various methods, see Ghosh (1994), Pfreffermann (2002), Rao
(1999). For a unified analysis of discrete and continuous data, Ghosh et al. (1998)
present hierarchical Bayes generalized linear models. The idea of Bayesian predictive
inference and Markov Chain Monte Carlo integration technique is particularly useful
for our problem at hand. In this study we extend the implementation to a zero-point
6
mass mixture distribution under the CMM model.
1.4 An outline of the dissertation
This dissertation is organized as follows. In Chapter II, a Bayesian mixture model
based data transformation is introduced for the meta-analysis of DNA microarrays.
An application of the meta-analysis approach to assimilate and analyze four inde-
pendent breast cancer microarray studies is discussed. Chapter III presents the use
of measurement error models for the analysis of tissue microarrays. I focus on the
parameter estimation and associated inferences in censored failure time regression
in the presence of measurement errors. Both a two-stage plug-in approach and a
joint model of the TMA core-level repeated measures and survival are introduced.
Chapter IV presents a Cell Mixture model as a generalized modeling framework for
the reconstruction of complex staining patterns from TMA experiments.
7
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Number of publications since 2001.
Figure 1.1: A Paradigm for Genomic Biomarker Development.
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CHAPTER II
A TWO-STAGE MIXTURE MODEL FOR
META-ANALYSIS OF MICROARRAY DATA
2.1 introduction
DNA microarray analysis has been shown to be a powerful tool in various aspects
of cancer research. With the increasing availability of published microarray data
sets, there is a tremendous need to develop approaches for validating and integrating
results across multiple studies. A major concern in the meta-analysis of DNA mi-
croarrays is the lack of a single standard experimental platform for data generation.
Expression profiling data based on different technologies can vary significantly in
measurement scale and variation structure. It poses a great challenge to compare
and integrate results across independent microarray studies. In a recent study of
diffuse large B cell lymphoma (DLBCL), Wright et al. (2003) sought to bridge two
different microarray platforms by validating findings from a cDNA lymphochip mi-
croarray using an independent dataset generated using Affymetrix oligonucleotide
arrays. Although the idea of training and testing classifiers is frequently used for
discriminant analysis, this application to distinct expression array platforms is less
common.
More systematic approaches have been proposed for integration of findings from
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multiple studies using different array technologies. Rhodes et al. (2002) have pro-
posed methods to summarize significance levels of a gene in discriminating cancer
versus normal samples across multiple gene profiling studies. By ranking the q-values
(Storey, 2002) from sets of combinations, a cohort of genes from the four studies was
identified to be abnormally expressed in prostate cancer. Choi et al. (2003) sug-
gested combining effect size using a hierarchical model, where the estimated effect
size in individual studies follows a normal distribution with mean zero and between
study variance τ 2. The effect size was defined to be the difference between the tumor
and normal sample means divided by pooled standard deviation. From a Bayesian
perspective, Wang et al. (2004) used data from one study to generate a prior dis-
tribution of the differences in logarithm of gene expression between diseased and
normal groups, and subsequent microarray studies updated the parameter values of
the prior. Assuming a normal error distribution, the differences were then combined
to form a posterior mean. Although phrased using different model frameworks, these
methods are similar in the spirit of combining the standardized differences between
two sample means across multiple studies. It has been shown, however, that the
overlap between significant gene detection on different array platforms is only mod-
erate due to low comparability of independent data sets (Mah et al., 2004). The large
variability brought in by microarray datasets using different platforms is expected
to affect the sensitivity and specificity of summary statistics constructed in various
ways across studies. Given the inherent differences of the microarray techniques, het-
erogeneity of the sample populations, and low comparability of the independently
generated data sets, meta-analysis of microarrays remains a difficult task.
A recent study proposed a Bayesian mixture model based transformation of DNA
microarray data with potential features applicable to meta-analysis of microarray
10
studies (Parmigiani et al., 2002). The basic idea is to estimate the probability of
over-, under- or baseline expression for gene sample combinations given the observed
expression measurements. With data-driven estimation of these quantities, one can
translate the raw expression measurement into a probability of differential expres-
sion. As a result, poe (i.e., probability of expression) was introduced as a new scale
and used in the context of molecular classification (Parmigiani et al., 2002). The
platform-free property of this scale, however, motivated us to incorporate poe in a
framework to meta-analyze microarray data. Several desirable features of using poe
as a new expression scale include the following: 1. poe provides a scaleless mea-
sure and thereby facilitates data integration across microarray platforms; 2. poe is
a model-based transformation with direct biological implications in the context of
gene expression data, as it is estimated based on a method that adopts an underly-
ing mixture distribution that accommodates over-, under-, and unchanged expression
categories; 3. poe unmasks differential expression patterns in microarray data by off-
setting the influence of extreme expression values (Scharpf et al., 2003); 4. Data
integration based on poe allows merging of samples on the unified scale rather than
using gene-specific summaries.
In recent publications of breast cancer microarray studies, several groups have
explored the hypothesis that the capacity to metastasize is intrinsic to the tumor
and therefore can be revealed by gene expression pattern. Four independent studies
have correlated gene expression profiles generated from distinct DNA microarray
platforms to breast cancer prognosis (Huang et al., 2003, Sorlie et al., 2001, Sotiriou
et al., 2003, van’t Veer et al., 2002). Among the four, Sorlie et al. (2001) and Sotiriou
et al. (2003), both cDNA microarray studies, applied unsupervised clustering and
identified several breast cancer subtypes characterized by differential expression of
11
a cohort of genes. Further, they correlated the tumor subtypes derived from the
expression profile with survival outcome and in both cases found that, as expected,
the ERBB2+ subtype correlated with shorter survival times. On the other hand,
van’t Veer et al. (2002), an inkjet oligonucleotide array study, and Huang et al.
(2003), an Affymetrix GeneChip study, have built classification models based on
gene expression profiles to predict 5-year or 3-year recurrence status. In all four
studies, however, the authors explored a common hypothesis that molecular profiles
were able to provide a more accurate prediction of patient survival compared with
clinical/pathological parameters. These studies therefore provided an excellent basis
for developing a meta-analysis of microarrays with regard to disease prognosis.
This Chapter is organized as follows. In section 2.2 and 2.3, we propose a two-
stage meta-analysis of microarrays with a focus on cancer prognosis prediction. In
section 2.4, we apply our method to the aforementioned breast cancer DNA mi-
croarray data sets. We demonstrated the advantage of a mixture model based
transformation for data integration and the gains of integrated data analysis over
single analysis. Such two-stage meta-analysis approach allows an inter-study vali-
dated meta-signature based on gene expression to be developed for more robust and
reliable cancer prognosis prediction across heterogeneous tumor samples.
2.2 Model based data transformation
Let xijk denote the preprocessed gene expression measurement for gene i from the
jth sample in the kth study, transformed using the base two logarithm, i = 1, . . . , N ,
j = 1, . . . , Mk, k = 1, . . . , K. We assume that data have been preprocessed, either
by a lowess normalization for two-channel microarray data (Yang et al., 2002) or a
robust analysis for Affymetrix data (Irizarry et al., 2003b). Then the available data
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can be summarized by {Xk}Kk=1, where Xk is a Mk by G matrix whose (i, j)th entry is
xijk. Note that the value and interpretation of xijk is inherently different across array
platforms and is not necessarily comparable if they are measured from independent
studies. Corresponding to xijk, let eijk be a variable that takes one of three values
{1, 0,−1}, indicating over-, baseline- or under- expression respectively for gene j in
sample i for the kth study. If eijk were known, then this is a variable that would
provide a platform-free scale which could be combined across multiple studies. We
approach this problem by treating eijk as a latent variable that is inferred from the
data using a mixture model.
2.2.1 A Normal-Uniform mixture distribution
We assume that xijk are realizations of the following mixture model:
xijk
iid∼ π+jkU(αik + µjk, αik + µjk + κ+jk) +(1− π+jk − π−jk)N(αik + µjk, σ2jk)
+ π−jkU(αik + µjk − κ−jk, αik + µjk) ,(2.1)
where αik + µjkis both the mean of the normal distribution and the boundary to the
two uniform distributions; αik is the sample effect with the constraint that
∑Mk
i=1 αik =
0; κ+jk and κ
−
jk provide limits to the uniform distribution in the mixture, and are set
to be at least 3σj. The parameters π
+
jk ≡ P (eijk = 1) and π−jk ≡ P (eijk = −1)
are the multinomial probabilities for the latent variable eijk. Conceptually, we can
think of gene expression arising from three populations of genes in model (2.1). The
first component in the model is the population of expression levels for genes that
are overexpressed in the cancer samples relative to the normal samples, the second
corresponds to genes that do not change between cancer and normal samples, and
the third is for genes that are underexpressed in cancer samples relative to normal.
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2.2.2 Posterior probability of differential expression
Let p+ijk ≡ P (eijk = 1|xijk) and p−ijk ≡ P (eijk = −1|xijk) be the conditional
probabilities of over and underexpression for gene j in sample i (over- and under-











jkf−1jk(xijk) + (1− π+jk − π−jk)f0jk(xijk)
,
where f0jk is the normal density function, and f1jk, f−1jk are the corresponding uni-
form densities for the differential expression categories for the jth gene in the kth
study. In the numerator of (2.2), f1jk = 1/κ
+
jk if xijk ∈ [αik + µjk, αik + µjk + κ+jk]
and 0 otherwise; whereas in the numerator of (2.3), f−1jk = 1/κ−jk if xijk ∈ [−κ−jk +
αik + µjk, αik + µjk] and 0 otherwise.
Note that the supports of the two uniform distributions are disjoint. As a result,












π−/κ− + (1− π+ − π−)f0
)
.
We then construct the following measure: pdijk = p
+
ijk − p−ijk, ranging from -1 to 1. It
can be interpreted as the signed conditional probability of differential expression of
gene j in sample i in study k. The interpretation and scale of the measure is portable
across array platforms and independent study data sets.
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2.2.3 Estimation using MCMC algorithms
In this situation, we assume that there is only k = 1 study. Let {Θj}Nj=1 generi-
cally denote the parameter in model (2.1) for gene j = 1, ...N . In the microarray data
setting, the total number of genes N can be a few thousands, leading to large amount
of gene-specific parameters. It is sensible to adopt a hierarchical Bayesian mixture
model setting for parameter estimation, where the variation of the gene-specific pa-
rameter estimates can be described by assuming prior distributions f(Θj|ψ) with
hyperparameter space ψ. In particular, let
µj ∼ N(ξ, τ 2), κ+j ∼ Exp(λ+κ ), logit(π+j ) ∼ N(ν+, ω+),
σ−2j ∼ Gamma(γ, λ) , κ−j ∼ Exp(λ−κ ), logit(π−j ) ∼ N(ν−, ω−).
In terms of prior choice, we follow the recommendations of Parmigiani et al. (2002).
To sample from the posterior distributions of the parameters, a Metropolis-Hastings
MCMC algorithm was then implemented where the gene-specific parameters were
repeatedly sampled from the corresponding full conditional distributions. These are
given in Appendix A. We thus fit the Bayesian algorithm to each microarray dataset
separately.
2.2.4 Linear rescaling
An alternative approach to integrating data across multiple datasets is to perform
a study-specific global normalization. For the kth study, let xkij ≡ (xij − x̄)/s.d.(xij)
be the globally scaled expression value for genej in sample i. Each study dataset is
then standardized to have zero mean and unit standard deviation. This yields a data
matrix, say X lk for the kth study. The linearly rescaled values can also be used for
data integration purposes in that expression values generated from different array
platforms are standardized to a common scale.
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Such an approach is much less computationally challenging compared to the mix-
ture model-based rescaling described in the previous section. However, there are
several advantages to the mixture model-based transformation. First, the method
incorporates biological information into estimating the posterior probabilities of ex-
pression. The transformed values carry meaningful interpretations as signed prob-
abilities of differential expression of a gene in a particular sample. Second, the
underlying normal and uniform mixture distributions give equal density in the tails
and is effective in reducing the influence of extreme expression values. And third,
the Bayesian hierarchical modeling approach borrows strength across genes resulting
in shrinkage-type estimators for a large correlated gene-specific parameter vector.
This is a method in which the high dimensional gene expression data are denoised.
We compare the performances of the two methods (mixture model-based and global
standardization) in Section 2.4.
2.3 Data integration and meta-analysis
2.3.1 Integration of transformed data
Let X∗k be the study-wise transformed expression data for the kth study. For the
mixture model-based transformation, X∗k = P
d
k , where P
d
k is a probability matrix with





k is the globally standardized logarithm expression matrix for the
kth study whose (i, j)th entry is xkij. For a common set of N genes that are profiled
in each of the study of interest, data integration is subsequently based on the rescaled




2.3.2 Classification methods for assessing meta-analysis pro-
cedures
We will assess the performance of the genes found using the meta-analysis methods
based on classification accuracy. A complication is that while most methods of
classification deal with data from two populations, the response with which we wish
to build classifiers to predict is time to breast cancer recurrence. While the ideal
data would be have information on time to recurrence on all subjects (potentially
censored), not all studies have the time to recurrence information available and
instead provide data on recurrence within a certain time interval (e.g., recurrence
within three years versus no recurrence within three years).
To deal with this issue, we will utilize a dichotomization. Let Ti be the event time
for subject i, Ci be the censoring time for subject i, and δi = 1{Ti < Ci} be the





1 δi = 1
0 δi = 0 and Ci ≥ t∗,
where t∗ can be specified with clinical knowledge. The low risk group yi = 0 has
to satisfy the additional constraint Ci ≥ t∗ to reduce potential bias introduced by
insufficient length of follow-up in certain cohort. This is particularly relevant in cross-
study analysis, given the potential heterogeneity in patient recruit criteria and study
designs. In this paper, we have chosen t∗ = 3 years. We then consider constructing
classifiers using y; note that y = 1 corresponds to the poor outcome group and y = 0
to the good outcome group. Across the 305 samples from the four studies, 51.1%
had y = 1.
Logistic regression was used to build a classifier for prognosis. For each gene j,
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we fit the following univariate logistic regression model using data from all studies:
logit{Pr(yi = 1|x∗ij)} = ηj + βjx∗ij,
where x∗ is the rescaled value that allows data integration across multiple studies.
The estimated values of βj, β̂j, are then used to form a risk score using a variation of
the compound covariate predictor method (Radmacher et al., 2002, Tukey, 1993); for
a given set of covariate values x1, . . . , xN , the risk index is given by RS =
∑N
j=1 β̂jxj.
If we want to assess the performance of the classifier, we must deal with the issue
of training and testing the model using the same data. An “honest” estimate of the





j , where i = 1, . . . ,
∑K
i=1 Mk, and β̂j,−i is the effect estimate
for gene j in the combined meta-cohort without the ith sample. The risk index for
sample i is a weighted linear combination of the expression profiles of the top p
genes, where the ranking of the genes is based on their corresponding significance
in the univariate logistic model fit. As a result, large positive values of RI indicate
high risk of failure, whereas large negative values of RI indicate low risk of failure.
Classification of sample i to the risk groups is then based on the ith leave-one-out
risk index. The classifier is C(X∗) = I{RIi > c}, with c being the empirical quantiles
of the RI ′s. The number of genes p in a classifier is also treated as a parameter and
optimized to minimize the prediction error rates.
2.4 Application to breast cancer data sets
Figure 2.1 depicts the workflow of applying the mixture model based meta-
analysis. In the following sections, details involved in each step of the data ap-
plication will be discussed.
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2.4.1 Data collection and preprocessing
The four breast cancer microarray datasets mentioned in the Introduction were
obtained at the author’s websites from four recently published studies. Numerical
descriptions of the studies are provided in Table 2.1. To perform the meta-analysis,
we focused on a common set of N = 2555 genes compiled across array platforms
by Unigene Cluster IDs that were present in all four studies. There are issues in
attempting to match genes from multiple studies with different platforms (Ghosh
et al., 2003), but we will ignore them in this paper. Because we are using genes
only if they are present in all four studies, we exclude many genes from the analysis.
While this leads to a loss of potential predictive features, it is not unreasonable to
assume that the common set across studies represents the most relevant genes of
interest for breast cancer prognosis.
Each data matrix of genes was then base-two log-transformed and normalized
by median centering and dividing by the standard deviation for each gene. The
mixture-model based approach requires complete data, missing expression values
were imputed by the k-nearest neighbors imputation algorithm (Troyanskaya et al.,
2001), with k = 10. As stated earlier, the goal of the analysis was to find a meta-
signature which represents genes that discriminate samples that are recurrence-free
for at least three years after surgery versus those that have recurrence within three
years.
The first stage of the analysis involves data-driven estimation of the signed prob-
ability of differential expression, namely pd = p+ − p−. The resulting values of pd
represent signed probability of differential expression for gene j in sample i, and thus
provide a unified measure across studies. In the second stage, the expression profiles
of tumor samples from multiple studies were combined on the pd scale to generate
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what we term a meta-cohort of genes. Class prediction for disease recurrence was
then assessed based on the combined data. We define the meta-signature to be the
optimal gene expression based classifier constructed in the combined data.
2.4.2 Identification of a 90-gene meta-signature
By minimizing the misclassification error in the meta-cohort via a leave-one-out
cross-validation, we obtained a 90 gene meta-signature that reliably predicts out-
come. This meta-signature classified 122 patients into a high risk group, where 84
(69%) of them had a recurrence. On the other hand, the signature classified 183
patients into a low risk group, where 118 (64%) of them did not recur by the end of
the followup. By cross-tabulating the risk groups predicted by the meta-signature
and the actual recurrence status, we obtained an estimated odds ratio of 4.0 (95%
CI: 2.5-6.5, P < 0.0001).
A heat map representation of the poe profile for the 90 gene meta-signature re-
vealed two distinct patterns of differential expression (Figure 2.2 top panel). Genes
display consistent differential expression probabilities (yellow indicate over-expression
and blue indicate under-expression) in the recurrent samples (R). By contrast, an ex-
ample of the individual signature (bottom panel) shows a cohort-specific expression
pattern that clearly can not be reproduced in independent data sets. In Figure 2.3,
functional annotation revealed genes involved in many important biological processes
such as cell cycle regulation (e.g., CDC28 protein kinase regulator subunit 2), cell
adhesion (e.g., chemokine C-X3-C motif receptor 1), and apoptosis (e.g., secreted
frizzled-related protein 4).
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2.4.3 Comparison of the meta-signature with study-specific
signatures.
To comprehend the potential gains of a two-stage meta-analysis over analysis of
a single dataset, we compared the performance of the meta-signature to that of the
individual signatures.
By minimizing the prediction errors, we obtained a set of individual signatures
consisting of 10, 60, 100, and 130 genes for the Sorlie, van’t Veer, Sotiriou, and Huang
studies, respectively. The results of the classifiers are summarized in Table 2.2. Not
only did the sizes of the study-specific signatures vary significantly, but the elements
of the signatures had very little overlap. At most two genes appeared in more than
one signature among the four. In addition, signatures identified in one study tended
to have poor prediction in other studies. These results are presented in Table 2.3.
Except for two cases (the Sorlie study signature in Huang study cohort and the
Sotiriou study signature in the van’t Veer study cohort), there was an increase in
classification error of approximately 20− 60% in the testing sets relative to training
sets.
The gene signature found by meta-analysis improves on the individual study-
specific signatures in two ways. First, its overlap with the study-specific signatures
ranged from 3− 40% (Table 2.2). The excluded genes are likely to be cohort-specific
findings that can not be replicated. By contrast, the meta-analysis is able to detect
genes that have slight signals in the individual analyses based on combining the data.
Second, the meta-signature recruited 41 genes not previously picked by any of the
single cohort signature, likely representing predictive features with small but consis-
tent effects previously masked in single studies. When comparing the performances
of the gene signatures, the meta-signature performed, on average, similarly to the
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individually optimized signatures in differentiating patients at low risk of recurrence
from those at high risk of recurrence in each single study cohort (Table 2.3, compar-
ing bottom row with the diagonals). This shows that the meta-signature can serve as
a common breast cancer recurrence index that is able to predict patient survival in
heterogeneous sample populations. When a gene signature built in one study cohort
performs differently in another, such meta analysis provides a solution to identify
a cross-study validated expression signature that holds across independent sample
cohorts.
2.4.4 Comparison with simple linear rescaling.
To study the potential benefit of data integration based on pd compared to that
based on xl, described in Section 2.2.4. We applied the same classifier to data com-
bined on global standardization and compared the model performances based on
data integrated by these two transformation strategies. Figure 2.4A shows that with
the pd transformation, misclassification rates steadily decreases as more genes are
used in the classifier. Performance based on the linearly rescaled data (Figure 2.4B),
however, is unpredictable. Figure 2.4C and 2.4D use a 90-gene meta-signature based
on the mixture model transformation and global standardization, respectively, for
predicting recurrence. The signature based on the signed probability of differential
expression (pd) is noticeably better than the signature based on the global stan-
dardization (xl), in differentiating patients at low risk of recurrence from those at
high risk of recurrence. Taken together, the mixture model based transformation
outperforms the linear rescaling method in combining multiple microarray data sets.
The meta-signature identified based on pd measures therefore offers more reliable
prediction of recurrence-free survival in the meta-cohort of breast cancer patients.
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2.4.5 Independent validation of the meta-signature
Independent validation of a gene signature is essential in assessing the true pre-
dictive value of the finding. Two data sets are considered for the validation of the
meta-signature. One includes 295 consecutive patients with primary breast carcino-
mas from the Netherlands Cancer Institute published in van de Vijver et al. (2002).
The second one published by Wang et al. (2005) consists of frozen tumor samples
from 286 patients with lymph-node-negative breast cancer who were treated at the
Erasmus Medical Center (Rotterdam, Netherlands) during 1980 to 1995. Figure 2.5
shows the validation Kaplan-Meier curves generated for the meta-signature and each
of the individual study signatures. It is clear that the meta-signature stands as the
most consistent performer of all. One of the individual signatures — the van’t Veer
70-gene — performs better than the other individual signatures in this validation
analysis, especially in Figure 2.5 (b). It should be pointed out that the van de Vijver
validation cohort is not strictly independent for the van’t Veer 70-gene signature as
part of the 295 samples were used to generate that particular signature (this also
affects the meta-signature, but to a less extent as other data sets are mixed in the
meta-cohort).
2.5 Discussion
Several important issues to consider when integrating microarray studies include
use of different gene expression measurement scales, varying analytical power and
reliability of the results for individual studies. To address these issues in a meta-
analysis framework, we proposed a two-stage mixture modeling strategy. The goal
of the mixture model-based transformation is to transform the preprocessed data to
the probability scale (pd = p+ − p−), which is then integrated across datasets. In
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particular, the signed probability of differential expression pd is easily interpretable
and is platform-independent. The Normal-Uniform mixture distribution under a
Bayesian hierarchical model setting has several desirable properties such as reducing
the influence of extreme tail elements; borrowing strength across genes for parameter
estimation; and shrinkage for the estimation of the correlated vector of the gene-
specific parameters.
At the second stage of the analysis, combining samples on the probability scale
mitigates the influence of potential artifacts from a single study. The effect is re-
flected on two counts. One, integrated sample cohorts improve the reliability of the
findings by guarding against false positive results from a single study. Two, it in-
creases the statistical power to detect small consistent effects that can be otherwise
masked by inadequacy of the sample size of an individual data set. By implementing
this modeling approach, we were able to combine information from four microarray
studies to build an inter-study validated meta-signature for predicting recurrence in
breast cancer patients.
As described earlier, a common set of 2555 genes was used in this meta-analysis,
as it is important to provide the same context for data-driven estimation of the
posterior probabilities. Although we assume the common set comprises the most
biologically relevant genes, the loss of potential predictive genes, however, may offset
the statistical power of the analysis. Alternative approaches to allow genes profiled
in some studies but not others is a topic for future research.
A distinction of the analysis presented here relative to those by other authors
(Rhodes et al., 2002; Wang et al., 2004) is that we sought to find genes that were
predictive of recurrence rather than predictive of diseased versus nondiseased sta-
tus. Given the heterogeneity of the tumors with respect to treatment response and
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survival outcome, a prognostic prediction analysis is generally more difficult because
it is a more complicated phenotype. Further, a prognostic signature (classifier) of
failure risk trained in one cohort is often times difficult to validate in independent
cohorts. The meta-analysis method presented here may potentially provide more
powerful gene signatures that are predictive of prognosis because they are validated
across multiple studies.
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Table 2.1: Description of the breast cancer gene expression datasets used in the meta-analysis.








Sorlie et al. Spotted cDNA 8102 58 23 35
van’t Veer et al. Inkjet oligonu-
cleotide
25000 78 44 34
Sotiriou et al. Spotted cDNA 7650 99 54 45
Huang et al. Affymetrix chip 12625 89 54 35
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Table 2.2: Comparisons of the signatures. Table lists the number of genes (Size), the number of
genes overlap with the meta-signature (overlap), and the prediction error rate for the
classifiers identified in individual study cohort and in the meta-cohort.
Signature
Sorlie van’t Veer Sotiriou Huang Meta
Size 10 60 90 140 90
Overlap 4 14 19 6 -
Prediction error rate 0.28 0.29 0.35 0.18 0.33
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Table 2.3: Comparison of the performances of the individual signatures and the meta-signature.
Table lists odds ratios (95% confidence interval) comparing the odds of actual recurrence
for those being classified as high risk to the odds of recurrence for those being classified
as low risk of recurrence by each signature.
Cohort
Signature(D) Sorlie (n=58) van’t Veer (n=78) Sotiriou (n=98) Huang (n=71)
Sorlie (10) 18.6 (5.0, 69.5) 2.1(0.8, 5.4) 2.3 (1.0, 5.3) 10.87 (3.5, 33.8)
van’t Veer (60) 3.1 (1.1, 9.2) 10.6(3.3,33.9) 4.1(1.7,9.7) 1.3(0.5,3.4)
Sotiriou (100) 1.7(0.6,5.0) 3.5 (1.4,8.9) 7.8(3.0,20.1) 1.5(0.6,3.7)
Huang (130) 5.1(1.6,15.7) 2.3(0.9,5.6) 0.9(0.4,2.0) 184.9(30.1,1137.2)
Meta (90) 25.0(4.2,149.0) 4.1(1.6,10.6) 6.0(2.5,14.5) 5.8(2.1,16.5)
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Figure 2.1: Diagram of the meta-analysis.
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Figure 2.2: Heatmap representation of the 90 gene meta-signature expression pattern (top panel)
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Figure 2.3: Top seven over-represented functional classes in the meta-signature.
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Low risk poe signature
High risk poe signature
Low risk se signature
High risk se signature
Figure 2.4: Comparison of model performances based on data integrated by the poe transformation
(A and C) and global standardization (B and D). A. Misclassification rates based on
poe transformation and B. based on global standardization. C. Performance of the 90-
gene signature built on poe and D. built on global standardized data in differentiating
patients at low risk of recurrence from those at high risk of recurrence.
32















































































































































































(a) Wang et al. data set (n=286)















































































































































































(b) van’t Vijver et al. data set (n=295).




EXPRESSION HETEROGENEITY IN TISSUE
MICROARRAY EXPERIMENTS
3.1 Introduction
DNA microarray technology has enabled expression measurement of thousands of
genes simultaneously, providing a platform for rapid screening of genomic biomarkers
in cancer. Translating these discovery-type findings into clinical relevance is a more
challenging task. Gene expression profiling studies using spotted cDNA arrays or
Affymetrix GeneChip arrays often yield a few hundred candidate cancer genes that
are associated with a phenotype. Only a small portion of these will be eventually
validated for the corresponding expression changes at the protein level. The advent
of Tissue Microarray (TMA) technology has provided a proteomic platform for such
validation studies to find clinically useful biomarkers. TMA experiments measure
tumor-specific protein expression via high-density immunohistochemical staining as-
says, allowing simultaneous evaluation of hundreds of patient samples in a single
experiment (Kononen et al., 1998). Since their initial development, TMA-based
expression studies have quickly become an integral part of cancer biomarker devel-
opment (Divito et al., 2004, Rubin et al., 2005, Seligson et al., 2005).
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A typical tissue array slide comprises up to 1000 tiny biopsy tissue elements, which
we will refer to as cores, with multiple cores corresponding to repeated sampling from
the same tumor. Expression measures on these replicate cores constitute the TMA
core-level data. These can display substantial within-subject variability for both
biological and experimental reasons. Biologically, for tumors that are highly infiltra-
tive and heterogeneous in nature (e.g., prostate tumors), protein expression pattern
can be quite variable. For example, cell proliferation genes often exhibit localized
high expression within a tumor, indicating elevated aggressiveness and metastatic
potential in the corresponding areas. Replicate sampling from various regions of
the tumor is therefore important in capturing the underlying heterogeneity within
a tumor. Experimental sources of the variability can come from a combination of
probe affinity, measurement imprecision, and further missing data due to insufficient
sampling. Without appropriately accounting for these variabilities, the noise-prone
measurements tend to attenuate the prognostic value of a potential biomarker in
predicting disease outcome. The lack of a model-based approach for TMA core-level
expression data to effectively model the intra-tumor variation has motivated us to
carry out a full investigation.
A good analogy for understanding TMA data structure is from probe-level data
generated by the Affymetrix GeneChip arrays. GeneChip arrays measure gene ex-
pression at the mRNA transcripts level. The probe-level data refer to the replicate
expression measures on a set of 16-20 small oligonucleotide probe sets derived for
a target gene. The biological variation comes primarily from these oligonucleotide
probe sequence variants, while experimental variations arise during the process of
slide printing, hybridization and optical reading. Li and Wang (2001) reported that
the variation of a specific probe across multiple arrays could be considerably smaller
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than the variance across probes within a probe set. Modeling Affymetrix probe-level
data has generated much attention (Irizarry et al., 2003a, Li and Wang, 2001) as the
technology has become more mature and widely used.
Similarly in TMA experiments, modeling within-tumor protein expression hetero-
geneity is an important problem. In these tissue-based experiments, the variation
across core samples within a tumor can be substantially larger than the variation ob-
served across subjects. Etzioni et al. (2005) used a compositional analysis to model
such heterogeneity, and compared the proportion of cells stained at different intensity
levels between normal and tumorous tissues. In this study, we focus on the effect of
modeling intra-tumor variation in the context of predicting patient survival outcome.
In a latent variable modeling framework, we assume that an underlying ‘true’ expres-
sion value predicts survival. In real experiments, this ‘true’ expression can not be
precisely measured due to sampling variabilities and measurement imprecision. In-
stead, one observes the core-level expression measurements that are subject to these
measurement errors. In a two-stage method, we adapt ideas from measurement error
modeling and propose a latent expression index (LEI) to approximate the underlying
true value, and focus on its behavior in proportional hazards models. Specifically, we
adapt an empirical Bayes estimator (Tsiatis et al., 1995) to 1) incorporate important
clinical parameters such as Gleason score and pathological stage of the tumor and 2)
adjust for the varying number of cores. We further establish a joint model for TMA
core-level data and survival outcome via a shared random effect. There is a large
literature on joint modeling of longitudinal data and survival (Brown and Ibrahim,
2003, Faucett and Thomas, 1996, Guo and Carlin, 2004, Henderson et al., 2000,
Tadesse et al., 2005, Wang and Taylor, 2001, Wulfsohn and Tsiatis, 1997, Xu and
Zeger, 2001). These methods have been developed predominantly for modeling sur-
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vival and CD4 counts in AIDS patients; here their application to Tissue Microarray
data in cancer biomarker studies is novel. Using both simulations and two published
TMA data sets, the performances of the naive, two-stage LEI, and the joint model
approach are compared in terms of the parameter estimates and associated inference.
The chapter is organized as follows. Section 3.2 specifies notation and models
for the TMA core-level expression data and for the patient survival data. Section
3.3 introduces LEI and its use in a two-stage method. Section 3.4 presents the
joint modeling approach and the Bayesian estimation framework. Simulation results
to compare the performances of these methods are then discussed in Section 3.5.
Case studies using two prostate cancer TMA data sets are presented in Section 3.6.
Further discussion can be found in Section 3.7.
3.2 Model specification
Measurement model for the TMA core-level data.
Let X∗i be the latent expression value for a biomarker in tumor i, i = 1, · · · , n.




i + Uij, j = 1, ..., ri; i = 1, ..., n,(3.1)
where we assume X∗i ∼ N(µx∗ , σ2x∗). The mean µx∗ is a linear function of clinical
covariates: µx∗ = θ0 + θZ
′
i, where Zi = (Z1i, Z2i, ..., Zpi) constitutes a row vector of
p clinical parameters characterizing histologic and pathologic features of the tumor;
and θ = (θ1, . . . , θp) is the associated p-dimensional row vector of effect sizes. In this
model, Uij represents the variation of the ri core-level expression measurements. We
assume Uij is i.i.d. N(0, σ
2





Let the observed survival time for patient i (i = 1, ..., n) be Ti = min(Yi, Ci),
where Yi is the time from diagnosis to disease recurrence; Ci is the time to censoring
which is independent of Yi, and δi = 1{Yi < Ci} is the censoring indicator. Under
the Cox proportional hazards model, the hazard rate for patient i is
(3.2) λ(t) = λ0(t)e
β∗X∗i ,
where λ0(t) is the baseline hazard function and β
∗ is the true regression coefficient.
We also consider a parametric Weibull regression model with the following form for
the hazard function:
(3.3) λ(t) = γtγ−1eβ0+β
∗X∗i .
3.3 Two-stage plug-in method
Given the basic assumption that the measurement error Uij has no predictive
value, i.e., λ(t|Xi, X∗i ) = λ(t|X∗i ), Prentice (1982) introduced the induced hazard
rate
λ(t|Xi) = λ0(t)eβ∗E[X∗i |Xi],(3.4)
and proposed to estimate β∗ by maximizing the corresponding partial likelihood.
Note that (3.4) is an approximation to (3.2). Define the Latent Expression Index
(LEI) to be an estimate of the conditional mean, LEIi = Ê[X
∗
i |Xi], for each subject i.
A two-stage plug-in method can be described by the following algorithm: 1) Compute
LEIi (i = 1, ..., n) as a surrogate expression estimate that adjusts for measurement
error; and 2) Apply the Cox or Weibull regression model using LEIi to obtain an
estimate of β∗ and the associated standard error.
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In the next section, we will describe methods for computing LEI for tissue mi-
croarray data. These include an empirical Bayes estimator conditional on clinical
covariates, a full Bayes approach and a Varying Replicate Number (VRN) method
as an extension to adjust for the number of cores per tumor.
3.3.1 Methods for computing LEI
The Empirical Bayes and full Bayes estimator.
Express (3.1) as a mixed effects model
(3.5) Xij = θ0 + θZ
′
i + νi + Uij,
where νi ∼ N(0, σ2x∗). The empirical Bayes estimator can then be derived as
(3.6) LEIebi = γ̂iX̄i + (1− γ̂i)(θ̂0 + θ̂Z′i),
where γ̂i ≡ σ̂2x∗(σ̂2x∗+ σ̂2ur−1i )−1 is the attenuation factor (Carroll et al., 1995). Param-
eter estimates {θ̂0, θ̂, σ̂2u, σ̂2x∗} can be obtained by fitting a mixed effects model as de-
scribed in (3.5), using a restricted maximum likelihood (REML) approach (Harville,
1977, Laird and Ware, 1982).
The empirical Bayes estimator conditions on the set of parameter estimates de-
rived from the data. The uncertainty of these estimates are not accounted for in
LEIeb. For this reason, a full Bayesian estimator, LEIfbi , is also considered. Hy-
perprior distributions are adopted as follows: σ−2u , σ
−2
x∗ ∼ Γ(r0, γ0). The full Bayes
estimator
LEIfbi = θ̃0 + θ̃Z
′
i + ν̃i,
is then based on the posterior inference from model (3.5) where {θ̃0, θ̃, ν̃i} are the
posterior means given the data.
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The Varying Replicate Number (VRN) method.
In a typical TMA construction, Ki cores are placed on the array for each tumor i.
However, not all of the measurements {Xi1, · · · , XiKi} are available. Several reasons
contribute to a varying number of replicate measure. These include heterogeneous
tissue composition and technical defects such as image corruption. The expression
measurement from non-tumorous tissue types or a corrupted image is typically con-
sidered unsuitable for an outcome analysis and excluded. Let Mij = 0, j = 1, · · · , Ki
indicate that the jth core from the ith tumor is lost due to the aforementioned reasons
and Mij = 1 if it is available. Expression measures are retained for ri ≡
∑Ki
j=1 Mij
cores, where ri varies across tumor samples and possibly depends on covariate Zi. We
assume ri to follow a Binomial distribution given Ki and P (Mij = 1) with possible
over-dispersion. The following logistic mixed effects model is adopted:
(3.7) logitP (Mij = 1) = ψ0i + ψZ
′
i,
where ψ0i ∼ N(ψ0, σ2ψ), Zi = (Z1i, Z2i, ..., Zgi) is the vector of g clinical covariates
that can be the same or different from those in (3.5), and ψ = (ψ1, ψ2, ..., ψg) is the
associated vector of coefficients. Therefore











The expression index under the VRN model is then derived by averaging over all the
possible values of (ri, Ki). In particular,
LEIvrni = E(ri,Ki)E[X
∗








































P̂ (Ki = s)
(3.9)
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An additional assumption for the above is that the expression measures do not cor-
relate with ri or Ki. Parameter estimates {θ̂0, θ̂, σ̂2u, σ̂2x∗} can be obtained by fitting
a mixed effects model as described in (3.5). A logistic mixed effects model in the
form of (3.7) was fitted to obtain {ψ̂0i, ψ̂}. Estimation is via methods described in
Lindstrom and Bates (1990) and McCulloch (1994). The empirical proportions were
used for P̂ (Ki = s).
In a relatively balanced TMA array where the number of replicate measures ri
does not vary much across subjects, γi ≡ σ2x∗(σ2x∗ + σ2ur−1i )−1 is an approximately
constant adjustment factor. The amount of shrinkage in LEIeb toward the overall
mean depends primarily on the ratio of the within- to between-subject variation in
that particular data set. In our example, however, ri is a highly variable quantity.
It exerts a larger role in determining how much weight LEIebi gives to a particular
subject’s data relative to the estimated population mean. The motivation for LEIvrn
is to provide a replicate number-averaged expression estimate that alleviates the
variability induced by ri in the empirical Bayes estimator.
3.4 Joint Modeling of survival and TMA core-
level data
The two-stage approaches described above are attractive for their simplicity and
straightforward interpretation. They require minimal computation and can be easily
implemented using existing statistical packages. However, there are major limitations
for the two-stage method (Tsiatis and Davidian, 2004). First, the two-stage method
involves a first order approximation and ignores the second-order term β∗
2
σ2(X∗i |X)
in the induced hazard rate function (3.4). As will be illustrated in the simulation
study, such approximation works well when β∗ is close to zero, but otherwise lead to
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sizeable bias in β̂∗. Second, parameter estimates in the second stage do not account
for the uncertainty in estimating LEI in the first stage. The associated standard
error for β̂∗ will be over-optimistic. Given these considerations, it is desirable to
make inference based on the joint likelihood of the failure time and TMA expression
data. In this study, a shared random effect model is adopted to induce correlation
between the TMA data and the survival outcome.
Given the measurement model specified in (3.5) for the TMA data, we write the
proportional hazards model for the survival outcome as




The parameter νi constitutes a shared random effect that connects the measurement
model (3.5) and the survival outcome model (3.10). The expression data and sur-
vival times are then assumed to be independent given νi. The joint likelihood for

















































We used a piecewise constant hazards model in which the time axis is partitioned
into L disjoint intervals, I1, ..., IL, where Il = [al−1, al) with a0 < ti and aL > ti for
all i = 1, ..., n. Assume a constant baseline hazard in the lth interval, λ0(t) = λl for
t ∈ Il. Rl is the set at risk at the beginning of interval l; dl is the number of failures
in interval l; and ∆il = min(ti, al)− al−1.
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Alternatively, a parametric Weibull model can be assumed for the survival out-
come using the following hazard function:
(3.13) λ(t) = γtγ−1 exp(b0 + bZ′i + β
∗νi).




∗νi). The survival time component of the joint likelihood in (3.12)










In a Bayesian estimation framework, the following prior distributions are specified
for the model parameters:
(β∗, θ0, θ, b0, b) ∼ N(µ0, σ20);
(σ−2u , σ
−2
x∗ ) ∼ Γ(r0, γ0);
(γ, λl, l = 1, ..., L) ∼ Γ(r0, γ0).
(3.15)
Relatively noninformative hyperparameters are chosen, in particular, µ0 = 0, σ
2
0 =
10000, r0 = 0.001, γ0 = 0.001. Samples from the posterior distribution are obtained
using Markov Chain Monte Carlo (MCMC) methods.
3.5 Simulation
3.5.1 Simulation Setup
The additive measurement error model in (3.5) with one covariate Z1i is used to
simulate the expression measure Xij, i = 1, ..., n, and j = 1, ..., ri. In this model,
θ0 = 0 and θ1 = 1. Furthermore, νi ∼ N(0, 1), Uij ∼ N(0, 0.5). The covariate Z1i is
simulated from a N(0, 1) distribution. The total number of cores sampled, Ki, takes
values in {1, 2, ..., 12} with P (Ki = 6) = 0.4, P (Ki = 1) = ... = P (Ki = 5) = 0.1,
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and P (Ki = 7) = ... = P (Ki = 12) = 0.017, mimicking the proportions from the
actual tissue array data set used in this study. The number of repeated measures
ri ≡
∑Ki
j=1 Mij is simulated from a Binomial(Ki, pi), where pi = 1− π1/Ki such that
the missing proportion equals π. The survival time Ti is simulated from a propor-
tional hazards model in the form of (3.2) with λ0(t) ≡ 1 and β∗ = 1 or 2. An
additional covariate Z1i is further assumed to associate with Ti with the coefficient
being one. The censoring time is simulated from an independent exponential distri-
bution that results in a 30% censoring proportion. Results are summarized over 100
such simulated data sets each of a sample size n = 200. In general, parameter values
are assigned in the simulation to mimic those for the real data sets.
Computation of LEIeb, LEIvrn were carried out using the PROC MIXED and
the IML procedure in SAS (SAS Institute, Cary, NC). LEIfb and the joint models
were implemented using OpenBUGS via the R interface BRugs (Spiegelhalter et al.,
2003, Thomas, 2004). We ran two chains with 1000 burn-in and 1000 updates per
chain for the MCMC convergence.
3.5.2 Simulation Results
The simulation results are summarized in Table 3.1. For β∗ = 1 in the survival
models, the naive approach (using X̄i as a surrogate expression) attenuates the true
effect size by around 25%. The coverage probability of a nominal 95% confidence
interval of β̂∗ is 0.10 at best. The two stage methods (LEI) achieved a considerable
bias correction by adjusting for the measurement error in the LEI imputation. The
joint modeling approach gives the best estimate β̂∗ = 1.03 and a coverage probability
of 95% compared to the truth.
Next a larger effect size is simulated (β∗ = 2). The bias in the two-stage ap-
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proaches due to the first-order approximation is evident. Overall the two-stage
methods generate less biased β̂∗’s compared to the naive estimate. Nevertheless,
these are 15-25% smaller than the true β∗. The coverages are poor for the two-stage
approaches. The joint modeling approach should be advocated in this scenario for
inference. Notice that the joint model estimates of β∗ are slightly bigger than 2,
especially under the Weibull distribution. This may be driven by the prior distribu-
tions adopted for the parameters under the Bayesian estimation scheme. We have
observed that such a difference disappears when the sample size gets larger.
3.6 Case study in prostate cancer
3.6.1 Data description
In this study, we consider two prostate tumor tissue microarray data sets. The
α-Methylacyl CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme
that plays an important role in fatty acid metabolism. AMACR has been shown
to consistently overexpress in prostate tumors (Rhodes et al., 2002). Rubin et al.
(2005) profiled AMACR protein expression using a TMA constructed on 203 prostate
tumors from a surgical cohort who underwent radical prostatectomy at the University
of Michigan as a primary therapy for clinically localized prostate cancer diagnosed
between 1994 and 1998. They found AMACR is a significant predictor of the Prostate
Specific Antigen (PSA) failure in these 203 patients.
The second biomarker evaluated in this study is BM28. BM28 encodes a highly
conserved mini-chromosome maintenance protein (MCM) that is involved in the
initiation of genome replication. Bismar et al. (2006) profiled a total of 41 genes (in-
cluding BM28) in a TMA-based proteomic study. They identified a 12-gene model
showing the expression combination of the twelve genes significantly associates with
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tumor progression and PSA failure in a set of 79 men following surgery for clinically
localized prostate cancer. The expression level of BM28 however did not show signif-
icant prognostic value in their analysis. We chose BM28 to evaluate the possibility
of its being a false negative biomarker due to measurement error.
For the AMACR data, an average of Ki = 5.5 (range: 2 to 12) tissue core speci-
mens were taken from each tumor sample and put on a tissue array for immunohisto-
chemical staining. After initial diagnostic evaluation of each core, an average of 29%
(range: 0-86%) of the cores were excluded due to reasons discussed earlier, leading
to 5.5% missing subjects. The BM28 data has a similar tissue array design. A quan-
titative imaging analysis of the staining intensity was obtained using the ACIS II
(Chromavision, San Juan Capistrano, CA) system. The intensity level ranges from
0 to 255 chromogen intensity units, and is transformed using the natural logarithm
(one unit added to avoid taking logarithm of 0) and normalized to have mean zero
and standard deviation one. Disease recurrence is defined as a serum PSA increase
>0.2ng/mL after radical prostatectomy. Censored observations are those free of the
recurrence at the time of last follow-up.
3.6.2 Measurement error and regression attenuation
Figure 3.1 illustrates a considerable amount of measurement error in the core-level
expression data from the two TMA experiments. In the AMACR data, methods-of-
moments estimates of the variance components are σ̂2u = 0.46 and σ̂
2
x∗ = 0.54. In
the BM28 data, the methods-of-moments estimates of the variance components are
σ̂2u = 0.62 and σ̂
2
x∗ = 0.21. The within-subject variation is almost three times the
between-subject variation.
In a Cox proportional hazards model context, we did a simple simulation where
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X∗i ∼ N(0, 1), β∗ = 1. A naive estimator X̄i = r−1i
∑ri
j=1 Xij —the average core-level
expression for tumor i— is used as the surrogate expression to replace X∗i in (3.2). We
simulate situations where measurement error is small (σ2u=0.1), moderate (σ
2
u=0.5),
and large (σ2x∗ = 1). Figure 3.2 shows various degrees of regression attenuation in the
estimate of β∗ as a function of replicate number ri and the amount of error σ2u. When
the parameter values are set to resemble the AMACR data, the naive estimate of β∗ is
approximately 30% smaller than the true value. With the current TMA construction
protocol specifying three cores per subject due to economic and tissue-preservation
reasons, and a great amount of within-subject variability routinely observed in the
core-level expression data, Figure 3.2 effectively conveys the importance of modeling
measurement error in TMA data. In the following two sections, we implement the
measurement error models to demonstrate how statistical inference differs from the
previous results.
3.6.3 AMACR expression and biochemical recurrence in prostate
cancer
In prostate cancer, Gleason score, pathologic stage and tumor size are among the
most important clinical parameters. We include these as clinical covariates Zi to
adjust in the measurement model (3.5), the replicate number model (3.7), and the
survival outcome model (3.10). In the measurement model, θ̂TumorSize = 0.32 with
an associated standard error of 0.13, indicating a marginal association of tumor size
with AMACR expression level. In the replicate number model, ψ̂TumorSize = 0.72
with an associated standard error of 0.16, which is consistent with our expectation
that a larger tumor sample provides more abundant number of cores.
Table 3.2 lists the estimates and associated standard errors (posterior standard
deviation) of β∗ in the outcome model. The measurement error adjustment has
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significantly improved upon the naive estimate. The error-adjusted β̂∗ is around 0.75
(ŝe(β̂∗) = 0.26), approximately 31% larger in absolute value than the naive estimate
which is 0.57 (ŝe(β̂∗) = 0.20). The amount of attenuation in β∗ is quite consistent
with what we conclude from the simulated datasets in the previous section. In this
dataset, the two-stage methods (LEIeb, LEIfb, LEIvrn) perform equally well as the
joint modeling approach. The simplicity and computational efficiency of LEI serves
as a satisfactory core-level expression index for AMACR. However as mentioned
earlier, the two-stage methods are based on a first-order approximation, the accuracy
of which is largely driven by the size of β∗ and the ratio of within- and between-
subject variation. As will be shown in the other data example, the two-stage methods
will not be always a suitable approach.
Kaplan-Meier curves are useful as a graphical representation of the prognostic
value of a biomarker. We examined these plots by dividing the subjects into different
risk groups based on the values of AMACR expression estimates derived under each
method. In Figure 3.3(a), subjects with AMACR high, median, and low expression
groups based on LEIvrn and the joint model estimates (C and D respectively) are
significantly better separated in terms of probability of recurrence-free survival, when
compared to that using the naive mean estimates (A).
3.6.4 BM28 expression and biochemical recurrence in prostate
cancer
The measurement model indicates a marginal association of pathologic stage of the
tumor with BM28 expression: θ̂PathStage = 0.59 (ŝe(θ̂) = 0.22). The replicate number
model again suggests a strong dependence on the size of the tumor: ψ̂Tumorsize =
1.12 (ŝe(ψ̂) = 0.43).
In Table 3.2, the differences under various models are more discernable in this
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datasets. First, the Weibull and piecewise exponential model overall generate slightly
different results given a small sample size (n=52). Second, the empirical Bayes
estimate differs substantially from the full Bayes LEI estimate. It is likely due to the
large uncertainties in the parameter estimates that determine LEIeb. Finally, the bias
introduced by the first-order approximation is prominent here. Both the coefficient
β∗ and the noise ratio in this dataset are much larger in magnitude compared to
the AMACR data example. In this case, the two-stage methods alleviate regression
attenuation, only to a limited extent. The joint model should be used for parameter
estimation and associated inference.
Figure 3.3(b) plots the Kaplan-Meier curves using different expression estimates.
The 5-year PSA recurrence-free survival probability is 0.95 (ŝe = 0.05) versus 0.58
(ŝe = 0.10) for low and high BM28 expression estimated by the joint model. Ad-
justing for measurement error in this dataset has made a dramatic change in the
conclusion about the prognostic value of BM28, compared to the naive method.
3.6.5 Improved expression estimates
Figure 3.4 compares the naive and the joint model expression estimates, plotted
against the survival time on the x-axis. The mean expression ± two standard de-
viations is plotted for each individual. Two improvements under the joint model
are clear: 1) the noise, represented by the error bars, is greatly reduced via the joint
modeling, and 2) the mean expression levels are distributed more tightly around a re-




In TMA data analysis, statistical methods often focus on downstream models in
predicting disease outcome assuming X̄i is a sufficient expression summary measure.
Relatively little attention has been given to the modeling of within-tumor variation
in these TMA experiments. As we have shown in this paper with real data examples,
analysis ignoring intra-tumor variation can lead to false negative results which are
tremendous wastes of valuable tissue resource and experimental costs. In this study,
we proposed both two-stage and joint analysis methods to analyze tissue microarray
data for bias correction. Adjusting for covariates Zi and the number of repeated
measures (Ki, ri) can further improve the efficiency of the expression estimates. Both
simulation and the case studies show that our methods outperform the common
approach in estimating the prognostic value of a biomarker.
The proposed error model assumes constant variance across all subjects. To test
the validity of this assumption, we performed the Levene’s test for homogeneity
of variance. The resulting test P-value is 0.003 and 0.04 for AMACR and BM28
respectively. There is some evidence suggesting a violation of the constant variance
assumption especially for the AMACR data set. It may be of interest to consider a
heteroscedastic model.
Since the initial development of TMAs, there have been many technical improve-
ments over the years. Recent advances in quantitative assessment of the immunohis-
tochemical staining provide precise, objective, and reproducible protein expression
measurements. Compared to the conventional pathologist scoring on an ordinal
scale, the Chromavision system used in our data examples enables quantification
of the antigen level on a continuous scale, free of the subjectivity associated with
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pathologist-based visual scoring system. AQUA (Camp et al., 2002), which stands
for Automated Quantitative Analysis, is an academic system that measures fluores-
cence signals, leading to higher sensitivity to very low antibody concentrations. In
addition, it allows the separation of tumor from stromal elements and the sub-cellular
localization of signals for a co-localization of the antigens in different cell compart-
ments. As the technology is becoming widely applied for cancer biomarker studies,
robust statistical analysis methods underpinning both biological and experimental
issues need to be established.
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Table 3.1: Simulation study. Results are summarized over 100 simulated datasets each of n = 200.
β̂∗ ŝe(β∗) sd(β̂∗) coverage β̂∗ ŝe(β∗) sd(β̂∗) coverage
Weibull Proportional Hazards
β∗ = 1 X∗ 1.01 0.08 0.08 0.96 1.01 0.08 0.08 0.97
Naive 0.75 0.07 0.08 0.10 0.75 0.07 0.08 0.09
LEIeb 0.93 0.08 0.09 0.85 0.93 0.08 0.09 0.87
LEIfb 0.93 0.08 0.09 0.85 0.93 0.08 0.09 0.88
LEIvrn 0.97 0.09 0.10 0.89 0.96 0.09 0.10 0.87
Joint Model 1.03 0.11 0.11 0.95 1.03 0.11 0.11 0.95
β∗ = 2 X∗ 2.05 0.12 0.12 0.95 2.03 0.11 0.10 0.94
Naive 1.13 0.08 0.10 0 1.18 0.08 0.11 0
LEIeb 1.51 0.11 0.13 0.03 1.58 0.11 0.13 0.06
LEIfb 1.48 0.11 0.12 0 1.55 0.10 0.12 0.04
LEIvrn 1.62 0.11 0.14 0.19 1.70 0.11 0.15 0.30
Joint Model 2.16 0.27 0.30 0.89 2.07 0.19 0.20 0.93
52
Table 3.2: A case study using prostate cancer TMA datasets.
β̂∗ ŝe(β∗) β̂∗ ŝe(β∗)
Weibull Proportional hazards
Naive -0.573 0.201 -0.571 0.198
AMACR LEIeb -0.761 0.266 -0.751 0.266
(n=203) LEIfb
†
-0.753 0.262 -0.752 0.263
LEIvrn -0.735 0.260 -0.737 0.258
Joint modeling† -0.742 0.268 -0.745[ 0.268
β̂∗ ŝe(β∗) β̂∗ ŝe(β∗)
Weibull Proportional Hazards
Naive 0.828 0.414 0.900 0.399
BM28 LEIeb 1.051 0.519 1.146 0.494
(n=52) LEIfb
†
1.457 0.564 1.493 0.504
LEIvrn 1.034 0.552 1.151 0.537
Joint Modeling† 1.753 0.766 1.592[ 0.600
† - Estimation is based on MCMC methods, where we sampled 2 chains each with 10000 burn-in and 10000 updates.
[We used J = 5 and J = 3 intervals for the piecewise exponential distribution in the AMACR and BM28 dataset
respectively. The estimate of the Weibull shape parameter is γ̂ = 0.71, and γ̂ = 0.97 from the joint modeling for
the AMACR and BM28 dataset respectively.
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Figure 3.1: Variance plots to represent the within-subject variation in the TMA core-level expres-
sion data. A) The AMACR data. Estimates of the variance components are: σ̂2u = 0.46
and σ̂2x∗ = 0.54. B) The BM28 data. Estimates of the variance components are:




























































Figure 3.2: A simulation demonstration of the bias in Cox regression coefficient estimate as a func-
tion of the number of repeated measures ri. The average bias with a 95% CI over 100




































































































(a) AMACR. The 10th and 25th expression quantile was used to divide the 203 patient
into three risk groups.
BM28 low
BM28 high




























































































(b) BM28. The median of the expression estimates was used to divide the 52 patients into
two risk groups.
Figure 3.3: Kaplan-Meier plots of prostate cancer recurrence. Patients are categorized into risk
groups based on the protein expression level of (a) AMACR and (b) BM28 profiled
using TMAs. The expression estimates are based on the A. Naive B. LEIeb C. LEIvrn
and D. Joint model.
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Figure 3.4: Comparison of the naive expression estimates (A, C) and the joint model expression
estimates (B, D). The top panel depicts the comparison in the AMACR data, the





EXPRESSION IN TISSUE MICROARRAY
STUDIES USING A CELL MIXTURE MODEL
4.1 Introduction
In Chapter III, I have presented methods for analyzing protein expression data
generated from Tissue Microarrays (TMAs). I focus on estimating the tumor means
of a biomarker adjusting for intra-tumor variability. In particular, a measurement
error model assuming normality is used to model the TMA core-level data with
repeated measurements. The number of repeated measures per tumor and clini-
cal/pathological covariates are incorporated to improve the precision of the expres-
sion estimates. A joint model relating the error model with patient survival infor-
mation is used to estimate recurrence risks. Through the study, the intensity of
the staining has been considered the relevant expression measure and specifically
modeled using measurement error approaches. A normal distribution assumption
on the log-transformed intensity measures is found to be sufficient for analysis pur-
poses. Nevertheless when a more heterogeneous staining pattern is encountered — a
mixture pattern composed of areas of non-staining (intensity equals zero) and areas
of positive staining, it is hard to model the protein expression using any standard
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distributional assumptions.
The motivation of this chapter is therefore to generalize the expression model for
reconstructing complex staining patterns. For this purpose, I introduce the concept
of a Cell Mixture Model (CMM). As illustrated in Figure 4.1, the basic idea can be
decomposed into the following aspects. 1) A tumor is represented by a population
of Ri cores (the total sampling capacity of a tumor); 2) The expression values in
each individual core is a mixture distribution with a point mass at zero (the non-
staining area); 3) The whole-tumor expression can be recapitulated by adding up
(e.g., weighted summation) the distributions of the expression values in all the cores.
The mathematical description will be put forward in Section 4.2.
There are difficulties of implementing the CMM model in TMA expression data.
First, the experimental data are only collected on a small number (ri out of Ri)
of random samples of cores. Generally speaking, the number of measured cores ri
often averages from 3-5 whereas Ri can be in the hundreds, though both may vary
proportionate to the size of the tumor. Second, each core is a very small sub-area
measured in millimeters compare to the whole tumor averaging around 1-2 centime-
ters (prostate tumors). When our interest is to obtain accurate estimates for tumor-
and core-level expression characteristics, sample-based methods will not be satisfac-
tory. An analogy is estimating the characteristics of the population in the United
States with data collected in three representative cities. In survey sampling problems,
small area estimation often involves parameter estimation for small sub-population
of interest. Hierarchical Bayes (HB) and Empirical Bayes (EB) approaches have
been effective with continuous data. For a thorough review of various methods, see
Ghosh (1994), Pfreffermann (2002), Rao (1999). For a unified analysis of discrete
and continuous data, Ghosh et al. (1998) present hierarchical Bayes generalized lin-
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ear models. The idea of Bayesian predictive inference and Markov Chain Monte
Carlo integration technique is particularly useful for our problem at hand. In this
study we extend the implementation to a zero-point mass mixture distribution un-
der the CMM model. Details of constructing the CMM expression estimators will
be discussed in Section 4.5.
Associating tumor-wise expression features with patient survival information is of
scientific interest in TMA studies. The prognostic value of a potential biomarker is
tested. Therefore accurate estimation of the disease risk associated with a biomarker
is essential. To achieve this, a joint modeling approach would be most effective where
the expression data and the survival data are simultaneously modeled. Markov
Chain Monte Carlo methods offer a convenient framework for complex problems
where analytic solutions are often unavailable or cumbersome. As will be discussed
in detail in Section 4.6, linking the CMM model on the expression data with survival
requires an imputation step within each MCMC iteration where draws are obtained
from posterior predictive distributions.
This chapter is organized as follows. Section 4.2 and 4.3 introduce the concept
along with the basic notation of the CMM model. In Section 4.4, a hierarchical
Zero-Augmented Gamma model is imposed for the quantitative expression measures
from tissue microarray experiments. Section 4.5 describes the construction of CMM
estimators based on a Bayesian imputation strategy and Monte Carlo integrations.
Section 4.6 extends the CMM model to jointly analyze TMA expression data and
patient survival outcome. Simulation studies are carried out in Section 4.7, and case
studies using two prostate cancer TMA data sets follow in Section 4.8. Conclusions
and further discussion can be found in Section 4.9.
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4.2 Notation and the Model
Figure 4.1 describes the concept of the cell mixture model. The cartoon illustrates
a tumor being dissected into a population of Ri tissue core samples. Each core
j (j = 1, · · · , Ri) captures a sample of cells stained at different intensities. Let aij(x)
denote the number of cells measured at staining intensity x, x ∈ [0,M ] in core j of
tumor i. Thus the density function can be expressed as gij(x) = aij(x)/nij, where nij
is the total number of cells in core j of tumor i. The total number of cells measured is
Ni ≡
∑Ri
l=1 nij. In Figure 4.1, each histogram is informative of gij, which is assumed
to be a mixture density with a point mass at zero for the non-staining area and some
density function f(·) for the positively stained area. In particular,
(4.1) gij(x) = (1− πij)I(x = 0) + πijf(x|µij, σ2ij)I(x > 0),
where πij denotes the proportion of staining; µij, σij are mean and variance param-
eters associated with the density f . Subsequently, the tumor-wise density function






where ωij = nij/Ni and
∑Ri
l=1 ωij = 1.
4.3 Description of the data
The tumor sampling scheme in TMA experiments has a ‘geographical’ clustered
sampling structure. Consider each tumor is a population of cells. Small areas of
0.6mm (cores) are taken from the tumor where cells within each area are measured
for protein expression. Let Xijk be the resulting intensity measure in tumor i (i =
1, · · · ,m), core j (j = 1, · · · , ri), and cell k (k = 1, · · · , nij). It needs to be pointed
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out that Xijk is an idealized measure where measurements can be taken per cell.
The current technology instead provides a crude mean intensity measure for cells





per core. As illustrated in Figure 4.2, Yij is the actual observed data whereas the
cell-level data are latent. The empirical estimate of µij is yij. For the zero-mass part,









respectively. And nij = n1ij + n0ij will be the total number of cells measured in
tumor i core j. The empirical estimate of πij is n1ij/nij.
4.4 A hierarchical Zero-Augmented Gamma model
In this section, we introduce a Zero-Augmented Gamma (hZAG) model for the
observed data.
4.4.1 Modeling the positive staining intensity




with mean µij, variance δµ
2
ij, and the coefficient of variation being 1/
√
δ. In our
application, we set δ = 0.2. The observed Yij subsequently adopts a Gamma distri-
bution with standardized shape and scale parameters. A Gamma-Inverse Gamma-

























iid∼ Normal(0, τ 2a ).
In this model, {µi1, · · · , µiri} denotes the vector of core-level random effects for
subject i and {a01, · · · , a0n} denotes the vector of subject-level random effects. Given
the Gamma-Inverse Gamma conjugacy, the marginal densities integrated over µij has
the following analytic form:













































where zi is a vector of tumor-level covariates and a is the associated coefficients.
4.4.2 Modeling the point mass at Zero
To model the point mass at zero in the mixture density of (4.1), we assume the
following hierarchical structure:
n1ij ∼ Bin(nij, πij),




where b0i ∼ N(0, τ 2b ), εij ∼ N(0, σ2b ), and zi can be the same or different than those
included in (4.3). Let b0ij = logit(πij) such that πij = exp(b0ij)/(1 + exp(b0ij)).
The core- and subject-level parameter spaces are
Θij = {µij, b0ij}, Θi = {a0i, a, τ 2a , ν, b0i,b, σ2b , τ 2b }
respectively (as illustrated in Figure 4.2). The likelihood function treating the latent
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To complete the hierarchy for the Bayesian model, the following prior distributions
are specified as:
ak ∼ N(µak , σ2ak), τ−2a ∼ Gamma(rτ2a , γτ2a ), ν ∼ Gamma(rν , γν);
bk ∼ N(µbk , σ2bk), σ−2b ∼ Gamma(rσ2b , γσ2b ), τ
−2
b ∼ Gamma(rτ2b , γτ2b ).
(4.7)
Posterior inference will then be based on the joint posterior distribution f(Θij,Θi|D).
Gibbs sampling is used to iteratively sample from the full conditionals of each pa-
rameter given the rest of the parameters and the data.
4.5 Estimation of tumor-wise expression charac-
teristics
In this section, I focus on estimating the tumor-wise protein expression character-
istics. Three quantities are of interest: the tumor-wise proportion of staining (πi),
mean intensity of staining (µ+i ), and a composite intensity (µi). Under the proposed













respectively. Here πij = exp(b0ij)/(1 + exp(b0ij)). For the rest of the Chapter, I use
ηi as a general notation for the above expression characteristics.
Assume independence among the cores and, without loss of generality, assume
the first ri cores from the ith tumor are observed and the rest of the cores are not
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where the first components of the expansion are estimable given the data D =
(
yij, n1ij, nij : i = 1, · · · , n; j = 1, · · · , ri
)
, and the second components involve latent
quantities Θmij where data are not observed for core j (j = ri + 1, · · · , Ri).
4.5.1 The CMM model-based estimator
To obtain a CMM model-based estimate of ηi, I propose the following in a
Bayesian framework. (1) The first component of (4.9) is computed based on a set of
draws Θ
(g)
ij = {b(g)0ij, µ(g)ij : g = 1, · · · , G} from the posterior density f(Θij|Θi,D)



















ij are then read-
ily obtained from the posterior samples. (2) Let Θmij ≡ (bm0ij, µmij )— the parameter
vector involved in the second component of (4.9). In the absence of knowledge about
Θmij , we replace the latent quantities with their expectation E[Θ
m
ij |D]. To calculate




Using Monte Carlo integration technique, we first draw Θi from their joint posterior
distribution f(Θi|D) and then simulate Θmij according to (4.3) and (4.5). Let {Θ(p)ij :
p = 1, · · · , P} be the set of predictive draws at each of the G MCMC iterations. The
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following quantities can then be computed:



















Similarly, we simulate a set of {µ(p)ij ,m = 1, · · · , P}, given Θ̃(g)i , for g = 1, · · · , G,
using (4.3) and obtain









































These are essentially imputation steps within each MCMC iteration. Assuming equal








































Since Ri À ri, (4.13) is dominated by the second component.
4.5.2 Sample-based estimators














These sample-based estimates are implied by the proposed model by setting σ2b = 0
in (4.5) and ν = 0 in (4.3) such that homogeneity is assumed across cores within a
tumor. These estimates are unbiased when the sample cores have the same charac-
teristics as the tumor.
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4.6 Joint analysis with patient survival outcome
Associating the expression characteristics to patient survival data is of major
interest in many TMA studies. A joint modeling approach would be the most effective
way to obtain accurate estimates of disease risks associated with a biomarker. To
extend the CMM model into a joint model with censored failure time data, we use a
piecewise constant hazards model in which the time axis is partitioned into L disjoint
intervals, I1, ..., IL, where Il = [al−1, al) with a0 < ti and aL > ti for all i = 1, ..., n.
Assume a constant baseline hazard in the lth interval, λ0(t) = λl for t ∈ Il. Rl is
the set at risk at the beginning of interval l; dl is the number of failures in interval
l; and ∆il = min(ti, al)− al−1. Further by treating the latent variables b0ij, µij as a























































































where Θij = (b0ij, µij). The following priors in addition to those specified in (4.7)
are chosen:
λl ∼ Gamma(rλl , γλl), β ∼ N(µβ, σ2β), κj ∼ N(µκj .σ2κj).(4.16)
The parameter spaces are expanded to:
Θij = {µij, b0ij}, Θi = {a0i, a, τ 2a , ν, b0i, b, σ2b , τ 2b }, Ωi = {λl : l = 1, ..., L, β, κ},
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where at the gth MCMC iteration, computation of ηi involves predictive draws and
Monte Carlo integration as discussed in the previous section. The details of the
MCMC implementation can be found in Appendix B.
4.7 Simulation study
4.7.1 Simulation setup
In the simulation study, we assign parameter values in the simulation to mimic
those for the real data sets. In particular, the parameter values under the hZAG
model are specified as follows: τ 2a = 0.01, σ
2
b = 1, τ
2
b = 1. The model has one covariate
Z1i simulated from N(0, 1) with associated model coefficient a1 = 0.5, b1 = 0.5.
For each tumor, ri is simulated from Binomial(10, 0.5). Simulation of Ri, the total
sampling capacity of a tumor, is relatively subjective as no information is available.
We simulate Ri from a Binomial(200, pi) where pi is allowed to vary with covariates
such as tumor size. The survival time Ti is simulated from a proportional hazards
model in the following form
(4.18) λ(t) = λ0(t)e
βηi+κ1z1i ,
with λ0(t) ≡ 1. The censoring time is simulated from an independent exponential
distribution that results in a 30% censoring proportion.
Parameter initialization is set up as follows. For Θ0i , crude estimates from fit-
ting a generalized linear mixed model using a Penalized Quasi-Likelihood approach
(Breslow and Clayton, 1993) are used. For the glmm fit, we use log- and logit- link
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respectively for the intensity and zero-mass model with Gamma and Binomial family
distribution. Next, to initialize the core-level parameters Θij, we use the empirical
estimates. Specifically, we set µ0ij = yij, b
0
0ij = exp(n1ij/nij)/(1 + exp(n1ij/nij)).
For the piecewise exponential model, a total of L = 4 intervals were chosen such
that each interval contains approximately equal number of events. We set λ0l to be
the empirical estimates of the event rate within each interval. Samples from the
joint posterior distribution is obtained by Gibbs sampling (Gelfand and Smith, 1990,
Geman and Geman, 1984). The full conditional density functions are specified in
Appendix B. Noninformative proper priors are chosen. All programming is done us-
ing the R programming language. For simulations, we discard the first 1000 samples
as the burn-in period. Every 10th sample is then retained to achieve a total of 1000
samples. Convergence is monitored using traceplots. Each simulation consisted of
100 replicate data, each of n = 100 subjects. Results are summarized over replicated
data sets.
Finally, we point out that in the intensity model, the marginal mean and variance
of Yij has analytic forms. A combination of penalized quasi-likelihood estimation
and BLUP estimation (termed PQL-BLUP) is therefore applicable. The details of
this estimation procedure can be found in Appendix C. We found the PQL-BLUP
estimates were similar to those obtained from the Bayesian estimation.
4.7.2 Simulation results
Model misspecification
Figure 4.3 illustrates the sensitivity to misspecified δ. We fit the CMM model with
δ = 0.2 whereas the true simulated value is 0.5. A, B, and C draws the fitted (dotted
line) and true (solid line) density of Xijk over the simulated latent data. Although
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the shape of distribution is somewhat sensitive to the value of δ, the density of
the observed measure f(yij|Θi) is not (D). Next, we simulate Yij from a log-normal
density function. Figure 4.4 reveals no serious model misspecification problems.
Accuracy of the expression estimates
To evaluate the accuracy of the sample-based estimates and the proposed CMM
model-based estimates in approximating the true expression quantity, the Mean
Squared Error (MSE), Absolute Relative Error (ARE), and Relative Difference (RD)




























Table 4.1 lists the mean of these statistics (taking median results in similar compar-
ison) over 100 simulated data sets. We chose different values for ν and σ2b to control
the amount of within-subject variation observed in Yij and n1ij respectively. When
the within-subject variance is relatively small, the difference between the sample-
based and the CMM estimates is not apparent. However, the amount of decrease in
MSE and ARE by the CMM estimator is incremental as the within-subject variation
gets larger. No significant bias is observed by examining the RDs in Table 4.1.
Joint modeling with survival
The interest in this section is to estimate the Cox regression coefficient β in (4.18).
Three approaches are compared. A naive method where the sample-based expression
estimates are plugged in a Cox model; a two-stage CMM method where the CMM
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estimates are plugged in the Cox model; and the joint modeling approach based on
the joint likelihood (4.15). The first two methods are considered two-stage methods
as compared to the joint model. The two-stage methods have several major limita-
tions. First, the survival information is not used in the CMM model to reconstruct
tumor expression, which can cause bias and efficiency loss in estimating β in the
second stage. Second, the uncertainty of estimating the expression quantity is not
assimilated in the second stage, leading to over-optimistic standard error estimates
of β̂. The joint modeling approach concurrently updates the CMM model and the
survival model by iteratively sampling through the joint posterior distribution of the
combined parameter space. We therefore expect more accurate inference from the
joint model. In Table 4.2, the top panel simulates βπi = 2, βµ+i = 0, βµi = 0, the
middle panel assumes βπi = 0, βµ+i = 2.5, βµi = 0, and the bottom panel assumes
βπi = 0, βµ+i = 0, βµi = 1.8. It is evident that the joint model performs best in terms
of the estimates and coverage probabilities for β̂. Furthermore, we examined the
effect of misspecified value for δ on the joint model estimates of β (results are shown
under Joint model* in Table 4.2). Specifically, δ is fixed to be 0.2 in the estimation
procedure while the true value in the simulated data set is 0.5. Such misspecification
has led to only small differences in estimating β in the joint model compared to the
correctly specified model. A possible explanation lies in the fact that the influence
of δ diminishes because of the standardization by nij (which is a large number) in
(4.3).
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4.8 Case study using prostate Cancer Tissue Mi-
croarray Experiments
4.8.1 Data description
The same prostate cancer TMA data sets used in Chapter III apply here. Details
of the data description can be found in the previous Chapter. Gleason score and
pathologic stage are included as the clinical covariates Zi. A batch effect is added
to the AMACR data set, as evident in Figure 4.5, the staining intensity distribution
is bimodal. In Rubin et al. (2005), an array-wise normalization was performed to
eliminate the batch effect resulting from experiment-to-experiment variation of im-
munohistochemical staining. For the MCMC convergence of the joint model, we use
the first 10,000 draws as burn-in, and retain every 20th draw till 1000 samples are
collected for inference. The approximate computing time to fit the AMACR data
set is 10 hours.
4.8.2 BM28 expression characteristics and patient survival
Figure 4.5 suggests that BM28 is a homogeneously stained marker. All of the 52
tumors showed over 94% staining. We therefore focus on analyzing the intensity of
the staining of this gene biomarker.
The top panel of Table 4.3 describes the performance of Cox regression models re-
lating the estimated mean intensity of BM28 to PSA-recurrence adjusting for Gleason
score and Pathological stage of the tumor. Among the two stage estimation proce-
dures of β, the CMM estimator of µ+i does not perform better than the sample-based
estimator. It is likely that the CMM estimates in the data set does not approximate
the true expression quantity significantly better than would the sample-based esti-
mates when ν is small (ν̂ = 0.006). As we have shown in the simulation study, the
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MSE and ARE differences are not discernable when the within-subject variation is
not too large. The joint model estimate is however more than two times larger than
those under the two-stage estimation. The estimated hazard ratio under the joint
model is 4.4 (95% CI:1.6-11.7 ) compared to 1.9 (95% CI: 1.2-3.0) estimated under
two-stage methods. However, a hypothesis test of H0 : β = 0 would give similar con-
clusions as the estimated standard error from the joint model is also substantially
larger than those from the two-stage estimation. After controlling for Gleason and
Pathological stage of the disease, the mean intensity of BM28 staining in the tumor
is a significant predictor of prostate cancer PSA-recurrence. A further notion is that
these results are consistent with those observed under the measurement error model
in Chapter III. The underlying Gamma-Inverse-Gamma assumption on the intensity
measure versus the log-normal assumption adopted previously does not seem to have
large influence on estimating the Cox regression coefficient β in the joint model.
4.8.3 AMACR expression characteristics and patient sur-
vival
Table 4.3 summarizes the results from analyzing the AMACR data set. A distinct
feature is the relationship between the expression characteristics. The composite
mean, µi, resembles (though not strictly equivalent to) an interaction term of the
proportion (πi) and the mean intensity (µi) of the staining fitted in the same model
adjusting for the Gleason score of the tumor and the stage of the disease. The
associated coefficient β̂µi is significant in both the two-stage CMM model and the
joint model. Another evidence of interaction is that when fitted individually, β̂πi and
β̂µi are close to zero (data not presented).
A second observation is that when comparing the naive model and the joint model
fitted in the AMACR data set, the regression coefficients are biased in different
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directions. Results in Table 4.3 suggest that βπi and βµi are underestimated while
βµ+i is overestimate. It should be pointed out that in this data set, we observe a
positive correlation between the proportion of staining and the intensity of staining.
The correlation coefficient between the sample-based estimates, π̂si and µ̂
s
i , is 0.80
and 0.53 for batch 1 and 2 respectively. When multiple error-prone covariates are
concerned in a regression model, the direction and magnitude of the bias can also
depend on the correlation between the predictor variables (Carroll et al., 1995).
Figure 4.9 reveals the complexity of AMACR protein expression as a predictor of
PSA recurrence outcome. Each of the three expression estimates are dichotomized
into two risk groups using the lower quartile as cutoff, resulting in a total of eight
combinations (though one group has 0 observations). Overall, the joint model (plot
B) demonstrates better differentiation of recurrence risks than the naive model (plot
A). In both figures, tumors demonstrating low staining proportion, low intensity,
and low composite intensity (curve 1) has the highest recurrence risk of all. One
significant difference between A and B lies in curves 3 and 4. The joint model has
generated substantially different estimates of the recurrence risks for these two groups
compared to sample-based methods.
4.9 Discussion
A cell mixture model is proposed to reconstruct tumor expression characteristics
from tissue microarray data. The concept is to assemble the whole-tumor expression
pattern from the subpopulation of tissue cores. We let each individual core density
adopt a zero-augmented Gamma density function to describe the proportion of non-
staining and the intensity of the positive staining respectively. A main difficulty
is model estimation. One wishes to obtain accurate estimates of both core- and
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subject-level parameters with an average of three cores per tumor. A hierarchical
Bayes model is therefore imposed to borrow strength across cores and across tumors.
We find that the reconstructed expression features are relatively robust under model
misspecification. Expression estimates under the CMM model have better accuracy
than the sample-based estimates. A joint model is presented to link the CMM
expression model with a survival model for censored failure time observations. The
implementation involves imputation steps within each MCMC iteration and Monte
Carlo integration technique. With the advent of modern computing power, complex
models are feasible. Simulation studies show that the joint model can effectively
reduce the attenuation of the disease risk estimates evident in two-stage methods.
In addition, when interactions among the expression features exist, relating noise-
inflated expression estimates to survival can lead to misleading results. Applying the
joint model effectively avoids erroneous interpretations of the risk estimates.
In this study, we estimated the percentage of staining, the mean intensity of stain-
ing, and a composite mean staining of a tumor from its reconstructed expression
distribution. These expression characteristics are further associated with censored
survival time to estimate recurrence risks in prostate tumors. In fact, exploring other
expression characteristics is possible given the reconstructed distribution under the
CMM model. For example, in addition to the mean, lower (e.g. 10th) or upper (e.g.
90th) percentile of expression may be a relevant quantity to summarize the tumor ex-
pression for biological reasons. In many TMA studies, with an average of three cores
observed for a tumor, the sample minimum (Yi(ri) = min1≤j≤ri yij) and the sample
maximum (Yi(1) = min1≤j≤ri yij) of staining are often used in place of a specific quan-
tile of expression. These sample-based statistics apparently target at a tail quantity
of the distribution of Yij, but their behavior is not clear. The sample maximum of
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one tumor may map to the 90th percentile of f(Yij), while the sample maximum of
another tumor may map to an entirely different percentile. In this respect, the CMM
model will allow more comparable and precise estimates of the expression quantiles,
while the Bayesian framework will provide a straightforward implementation where
any percentiles of the posterior samples can be readily obtained.
In our current model, we assume the proportion of staining and the intensity of the
staining are independently distributed given covariates Zi. To relax such conditional
independence assumption made for the CMM model, a random effect can be added
to induce correlation between the zero-mass and the intensity model. Such extension
is useful when a biomarker has inherently correlated expression pattern whereas the
















































































































































































































































































































































































Table 4.2: Cox regression. Results are summarized over 100 simulated data sets each of n = 100.
The CMM model parameter values are simulated to be the same as in Table 4.1.
true β β̂ sd(β̂) ŝe(β) coverage
πi 2 2.06 0.24 0.23 0.97
π̂si 1.48 0.23 0.18 0.27
π̃cmmi (2stg) 1.60 0.22 0.22 0.53
Joint model 2.06 0.32 0.40 0.97
Joint model* 2.07 0.30 0.36 0.97
µ+i 2.5 2.50 0.30 0.26 0.93
µ̂+si 1.43 0.25 0.23 0.39
µ̃+cmmi (2stg) 2.07 0.27 0.23 0.44
Joint model 2.48 0.55 0.49 0.94
Joint model* 2.55 0.51 0.52 0.94
µi 1.8 1.82 0.21 0.20 0.95
µ̂si 1.40 0.18 0.16 0.48
µ̃cmmi (2stg) 1.68 0.16 0.19 0.79
Joint model 1.75 0.41 0.47 0.95
Joint model* 1.73 0.40 0.44 0.95
*Joint model under misspecified δ.
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Table 4.3: Case study using prostate cancer TMA data sets. Prediction of patient PSA-recurrence
using tumor-wise protein expression estimates.
BM28 (n=52)
Sample-based CMM (2stg) Joint model
β̂ ŝe(β) β̂ ŝe(β) β̂ ŝe(β)
µ+i 0.668 0.232 0.630 0.236 1.481 0.501
Gleason 0.666 0.601 0.683 0.561 0.592 0.558
Stage 0.938 0.507 0.837 0.535 0.822 0.501
AMACR (n=203)
Sample-based CMM (2stg) Joint model
β̂ ŝe(β) β̂ ŝe(β) β̂ ŝe(β)
πi 0.827 0.358 1.284 0.539 1.778 0.586
µ+i -1.132 0.464 -0.554 0.402 -0.488 0.389
µi -0.736 0.457 -1.008 0.458 -2.372 0.728
Gleason 1.237 0.418 1.177 0.42 1.025 0.513
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Figure 4.1: A conceptual model for the whole tumor. Each tumor i represented by a population of
Ri cores.
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Figure 4.2: Model structure
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Figure 4.3: Sensitivity to misspecification of δ. (A, B, C) plots the fitted (dotted line, assuming
δ = 0.2) and the true (solid line, δ = 0.5) density of Xijk over the histogram of the
latent data. (D) shows the fitted and true density curves of the observed data over the
histogram of Yij , j = 1, ..., Ri.







































































Figure 4.4: Model misspecification. Here Yij is simulated from a log-normal (LNN) distribution
with mean µi = a0i + azi and variance σ2 = 0.01. Solid lines are the LNN density












































































ν̂=0.006   τ̂a
2
=0.01
Figure 4.5: Histograms of the percentage of staining and the intensity of staining. The estimated
variance parameters in the CMM model are indicated in the plots. For the AMACR
data, the batch effect for the Gamma-Inverse-Gamma model is listed.
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(a) BM28 protein expression in four different tumors
























































































(b) AMACR protein expression in four different tumors
Figure 4.6: Reconstructed tumor expression under the CMM model.
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Figure 4.7: Kaplan-Meier plots. Patients are categorized into risk groups based on the protein
expression estimates (A: Sample-based, B: Joint model). The lower quartiles are used
for dichotomization. 1. low πi, low µ+i , low µi, 2. low πi, high µ
+
i , low µi, 3. low πi,
high µ+i , high µi, 4. high πi, low µ
+
i , low µi, 5. high πi, low µ
+
i , high µi, 6. high πi,
high µ+i , low µi, 7. high πi, high µ
+




The use of genomic and proteomic approaches has revolutionized cancer research
in the past decade. Cutting-edge technologies such as DNA microarrays and Tis-
sue Microarrays (TMAs) have provided high-throughput platforms for identifying
and validating genome biomarkers for cancer diagnosis and prognosis. Developing
meaningful and robust statistical methods is a key element for reliable and repro-
ducible findings. In this dissertation, I address some of the statistical issues related
to biomarker studies using microarray data.
In Chapter II, I presented a Bayesian mixture model approach to the meta-analysis
of DNA microarrays. The estimated probability of differential expression, poe, is
used as a unified scale to eliminate array platform differences. Data integration
based on poe has several advantages in a meta-analysis context. One, integrated
sample cohorts improve the reliability of the findings by guarding against false pos-
itive results from a single study. A meta-signature is therefore more likely to be
validated in independent data sets. Two, data integration increases the statistical
power to detect small consistent effects that can be otherwise masked by inadequacy
of the sample size of an individual data set. The utility of such meta-analysis frame-
work is broad with the increasing amount of publicly accessible microarray data.
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Choi et al. (2007) (submitted manuscript) extended the application in prostate can-
cer to compare metastatic and localized disease across multiple microarray stud-
ies. Two softwares, POE (Parmigiani et al., 2002) and MetaArray (Choi et al.,
2007), that implement MCMC methods are available to generate poe values from
raw expression data. They can be downloaded from the R Bioconductor project
(http://www.bioconductor.org).
Although the poe transformation eliminates the measurement scale differences
across array platforms, additional steps can be taken to improve the reproducibility
of the gene expression profile from experiment to experiment. For example, in the
proposed meta-analysis strategy, compiling common genes across array platforms is
an important step. Matching probes across cDNA arrays and Affymetrix arrays to
ascertain they target at the same full-length mRNA transcript is hardly a straightfor-
ward task. Unigene ID is a common choice for cross-platform mapping, but several
studies have found that Unigene ID alone is insufficient for matching and often lead
to poor correlation between gene expression across platforms. Sequence matching
based on RefSeq database can significantly improves the quality of matches and sub-
sequently increase the cross-platform consistency and reproducibility (Ji et al., 2006,
Mecham et al., 2005).
In Chapter III, I have addressed statistical issues in analyzing protein expression
data from tissue microarray experiments. A Latent Expression Index (LEI) is intro-
duced to adjust for 1) the intra-tumor variability, 2) the number of repeated measure
per tumor, and 3) clinical covariates. As a validation tool, accurate estimation of
the disease risk associated with a biomarker from TMA data is essential. A joint
model is proposed for simultaneous inference on the expression data and patient
survival information. Both simulation studies and data application have shown that
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the joint model is an effective approach to eliminate the attenuation in the coeffi-
cient estimates caused by measurement error. In this study, our primary interest is
parameter estimation in proportional hazards models with variables measured with
error. The proposed joint model is useful in eliminating bias in estimating the Cox
regression coefficient. However, it should be pointed out that such error model is not
necessary when prediction of the outcome is concerned which is beyond the scope of
this dissertation.
In Chapter IV, a Cell Mixture Model (CMM) is proposed to reconstruct complex
tissue staining patterns in TMA experiments. The concept is to assemble the whole-
tumor expression pattern by aggregating over the subpopulation of tissue cores. Each
individual core is assumed to be a zero-augmented distribution to assimilate the
non-staining areas and the staining areas. A hierarchical Bayes model is imposed to
borrow strength across cores and across tumors. A joint model is presented to link the
CMM expression model with a survival model for censored failure time observations.
The implementation involves imputation steps within each MCMC iteration and
Monte Carlo integration technique. Possible future work includes correlating the
proportion of staining and the intensity of the staining in the CMM model.
In summary, the existing methods in TMA studies have two major limitations:
1) they generally treat the expression measures as error-free quantities and 2) there
is a lack of a unified modeling approach to incorporate both staining proportion and
intensity measure. The main contribution of Chapter III and IV is to provide meth-






FULL CONDITIONAL DISTRIBUTIONS FOR CHAPTER
II
In the meta-analysis, the following gene-specific parameters were repeatedly drawn
from the full conditional distributions as shown below
κ+
(t+1)
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ij )(xij − x̄(t)j )2, and Mk is the sample size for study k; .
The derivation of these conditionals is fairly standard; see Diebolt and Robert (1994).
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APPENDIX B
FULL CONDITIONAL DISTRIBUTIONS FOR CHAPTER
IV










































































































































































































































































rλ + dl, γλ +
∑
i∈Rl
∆il exp {βηi + κz′i}
)
.
In the above G denotes a Gamma distribution; IG denotes an Inverse-Gamma dis-
tribution; b is a 1×K row vector of coefficients.
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APPENDIX C
PQL-BLUP ESTIMATION FOR THE INTENSITY
MODEL IN CHAPTER IV
Given the conditional mean and variance
E[yij|a0i, a, z] = ea0i+az′i









we estimate (α0i, a) by a PQL approach Breslow and Clayton (1993) via maximizing








































conditional on (â0i, â, µ̂ij). In this estimation procedure, δ is fixed to be 0.2 as part
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